Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Journal for ImmunoTherapy of Cancer · 2026
DOI: 10.1136/jitc-2025-013384 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Yu Sato und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, The University of Osaka, Suita, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Antibodies, Monoclonal, Humanized, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Background
Atezolizumab plus bevacizumab (Atez/Bev) has become the first-line therapy for unresectable hepatocellular carcinoma (HCC). However, reliable biomarkers to predict therapeutic response remain lacking.
Methods
We conducted a high-throughput plasma proteomic screen using the Olink proximity extension assay to identify predictive biomarkers in 78 patients with unresectable HCC treated with Atez/Bev. Validation was performed in an independent cohort of 89 patients. Tumorous expression of the lead candidate, carbonic anhydrase 9 (CA9), was examined using transcriptomic and single-cell analyses. Functional studies were performed in a syngeneic mouse model using Car9-overexpressing hepatoma cells, treated with anti-programmed death-ligand 1/vascular endothelial growth factor antibodies, with or without a CA9 inhibitor.
Results
High plasma CA9 levels were significantly associated with poor objective response rate, disease control rate, progression-free survival, and overall survival in both discovery and validation cohorts. Multivariable analysis confirmed CA9 as an independent predictor of treatment resistance and poor outcomes. Tumorous CA9 expression correlated strongly with circulating CA9 and was restricted to malignant cells. In vivo, tumors overexpressing Car9 showed resistance to Atez/Bev therapy, characterized by reduced CD8+T cell infiltration, suppressed cytotoxic gene expression, enrichment of M2-like macrophages, and pro-angiogenic signaling. The addition of a CA9 inhibitor reversed resistance and restored antitumor efficacy of Atez/Bev in this model.
Conclusions
Tumor-derived circulating CA9 is a predictive biomarker and functional driver of resistance to Atez/Bev therapy in HCC. Targeting CA9 may enhance therapeutic response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, The University of Osaka, Suita, Japan.
- Department of Gastroenterology and Hepatology, The University of Osaka, Suita, Japan t-kodama@gh.med.osaka-u.ac.jp.
- Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan.
- Department of Gastroenterology and Hepatology, National Hospital Organization Osaka National Hospital, Osaka, Japan.
- Department of Gastroenterology and Hepatology, Osaka Police Hospital, Osaka, Japan.
- Department of Gastroenterology and Hepatology, Ikeda Municipal Hospital, Ikeda, Japan.
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Sato, Y., Kodama, T., Maesaka, K., Kai, M., Murai, K., Tahata, Y., Saito, Y., Nakabori, T., Ohkawa, K., Tanaka, S., Sakamori, R., Miyazaki, M., Furuta, K., Ishida, H., Matsumoto, K., Tawara, S., Yakushijin, T., Nozaki, Y., Hosui, A., …, & Takehara, T. (2026). Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-013384
Vancouver
Sato Y, Kodama T, Maesaka K, Kai M, Murai K, Tahata Y, et al. Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2025-013384
BibTeX
@article{Sato2026,
author = {Sato, Yu and Kodama, Takahiro and Maesaka, Kazuki and Kai, Machiko and Murai, Kazuhiro and Tahata, Yuki and Saito, Yoshinobu and Nakabori, Tasuku and Ohkawa, Kazuyoshi and Tanaka, Satoshi and Sakamori, Ryotaro and Miyazaki, Masanori and Furuta, Kunimaro and Ishida, Hisashi and Matsumoto, Kengo and Tawara, Seiichi and Yakushijin, Takayuki and Nozaki, Yasutoshi and Hosui, Atsushi and Nishio, Akira and Tatsumi, Nobuyuki and Kakita, Naruyasu and Yoo, Changhoon and Fukai, Moto and Taketomi, Akinobu and Hikita, Hayato and Tatsumi, Tomohide and Takehara, Tetsuo},
title = {Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
doi = {10.1136/jitc-2025-013384}
}
EUVIMED